Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.